Under construction – not a live service
Sign in
Not yet taking people in FranceNo phase

Looking for Gene Changes in Families With Multiple Sclerosis and Related Diseases

Studies blood and genes in families with several members affected by these diseases.

Plain-language title generated from the registry record
Registry title: Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health

Key facts

Where
Bron, Nantes, Nice, Paris, and Rennes, FranceSee the 5 sites

Where in France

  • Hospice Civil de Lyon - Hospital Pierre WertheimerBron, FranceNo longer taking part
  • University Hospital LaennecNantes, FranceNo longer taking part
  • University Hospital Pasteur 2Nice, FranceNo longer taking part
  • Assistance Publique Hôpitaux de Paris- La Pitié Salpêtrière HospitalParis, FranceNo longer taking part
  • University Hospital PontchaillouRennes, FranceNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Institut National de la Santé Et de la Recherche Médicale, France
Trial code
NCT07902479
Record updated
4 November 2026
Original description
The goal of this observational study is to learn why some families have several members with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or MOG antibody-associated disease (MOGAD). These diseases happen when the immune system attacks the brain, optic nerves, or spinal cord. The study includes about 500 people from about 100 families: people with one of these diseases and their relatives who do not have it. The main question is: Do rare gene changes (variants) shared by family members explain why these diseases run in families? Researchers will compare the DNA of family members who have the disease with the DNA of relatives who do not. They will also look at how genes are switched on and off in blood cells. Participants will:Read full original descriptionShow less

Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health

The goal of this observational study is to learn why some families have several members with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or MOG antibody-associated disease (MOGAD). These diseases happen when the immune system attacks the brain, optic nerves, or spinal cord. The study includes about 500 people from about 100 families: people with one of these diseases and their relatives who do not have it. The main question is: Do rare gene changes (variants) shared by family members explain why these diseases run in families? Researchers will compare the DNA of family members who have the disease with the DNA of relatives who do not. They will also look at how genes are switched on and off in blood cells. Participants will:

* Attend one visit of 2 to 3 hours at one of five French hospitals * Answer questions about their health, treatments, and family history * Give a 50 mL blood sample

Inclusion: Affected participants:; Age 15 years and 3 months or older; Multiple sclerosis (2024 McDonald criteria), neuromyelitis optica spectrum disorder with anti-AQP4 antibodies (2015 Wingerchuk criteria), or MOG antibody-associated disease (2023 international MOGAD panel criteria); Member of a multiplex family: at least two affected members sharing at least 12.5% of their genetic heritage; Affiliated to a social security scheme or equivalent; Written informed consent (for minors: assent of the minor and consent of the holders of parental authority); Unaffected relatives:; Age 18 years or older; Sharing at least 25% of genetic heritage with one of the two affected family members; No multiple sclerosis, NMOSD, MOGAD, or other known inflammatory disease of the central nervous system; Affiliated to a social security scheme or equivalent; Written informed consent; Transcriptomic sub-cohort (30 to 60 participants, about 10 families):; Patients with no immunomodulatory or immunosuppressive treatment for at least 12 months, and their relatives.

Exclusion: Refusal to participate before the inclusion visit; Inability to understand the study information or to consent; Person under guardianship, curatorship or legal protection; Person deprived of liberty by judicial or administrative decision; Pregnant or breastfeeding woman; No kinship with at least one affected member of the included family; Refusal to be informed of an incidental discovery of a pathogenic genetic variant.

ClinicalTrials.gov NCT07902479